For research use only. Not for therapeutic Use.
Xanthine oxidase (XO) inhibitor. Niraxostat demonstrated high oral bioavailability being predominantly eliminated via the liver. It potently reduces serum uric acid levels. Niraxostat was in clinical trials for the treatment of gout.
KEYWORDS: Niraxostat | Supplier | XO inhibitor | Y700 | Piraxostat | Y 700 | Y-700 | CAS [206884-98-2] | Hypoxanthine | Xanthine Oxidase | Inhibitor | Enzymes
Niraxostat
| Catalog Number | I033326 |
| CAS Number | 206884-98-2 |
| Molecular Formula | C16H17N3O3 |
| Purity | ≥95% |
| IUPAC Name | 1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]pyrazole-4-carboxylic acid |
| InChI | InChI=1S/C16H17N3O3/c1-16(2,3)10-22-14-5-4-13(6-11(14)7-17)19-9-12(8-18-19)15(20)21/h4-6,8-9H,10H2,1-3H3,(H,20,21) |
| SMILES | CC(C)(C)COC1=C(C=C(C=C1)N2C=C(C=N2)C(=O)O)C#N |
| Reference | Fukunari A. et al. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic Acid]: A Potent Xanthine Oxidoreductase Inhibitor with Hepatic Excretion. JPET 2004, 311, 519-528. |
